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beta-blockers in heart failure: rationale
and design
Dipak Kotecha1,2*, Luis Manzano3, Douglas G Altman4, Henry Krum2, Guliz Erdem1, Nicola Williams4
and Marcus D Flather5 on behalf of the Beta-Blockers in Heart Failure Collaborative GroupAbstract: The Beta-Blockers in Heart Failure Collaborative Group (BB-HF) was formed to obtain and analyze
individual patient data from the major randomized controlled trials of beta-blockers in heart failure. Even though
beta-blockers are an established treatment for heart failure, uptake is still sub-optimal. Further, the balance of
efficacy and safety remains uncertain for common groups including older persons, women, those with impaired
renal function and diabetes. Our aim is to provide clinicians with a thorough and definitive evidence-based
assessment of these agents. We have identified 11 large randomized trials of beta-blockers versus placebo in heart
failure and plan to meta-analyze the data on an individual patient level. In total, these trials have enrolled 18,630
patients. Uniquely, the BB-HF group has secured access to the individual data for all of these trials, with the
participation of key investigators and pharmaceutical companies.
Our principal objectives include deriving an overall estimate of efficacy for all-cause mortality and cardiovascular
hospitalization. Importantly, we propose a statistically-robust sub-group assessment according to age, gender,
diabetes and other key factors; analyses which are only achievable using an individual patient data meta-analysis.
Further, we aim to provide an assessment of economic benefit and develop a risk model for the prognosis of
patients with chronic heart failure.
This paper outlines inclusion criteria, search strategies, outcome measures and planned statistical analyses.
Trial registration: Clinical trial registration information: http://clinicaltrials.gov/ct2/show/NCT00832442
Keywords: Beta-blockers, Heart failure, Meta-analysis, Design paperBackground
Heart failure (HF) is a major public health problem with
both incidence and prevalence rising rapidly along with
associated healthcare costs, estimated to be $39.2 billion
in the United States and £625 million per year in the UK
[1,2]. HF accounts for around 5% of all hospital admis-
sions and re-admission rates approach 50% over the fol-
lowing 12 months. Prior to the 1990s, beta-blockers were
considered to be contraindicated in HF. With an increased
understanding of the pathophysiology of HF, the hypo-
thesis developed that beta-blockers may alleviate inappro-
priate sympathetic drive, reduce heart rate and allow* Correspondence: dipak.kotecha@monash.edu
1Clinical Trials and Evaluation Unit, Royal Brompton Hospital, Sydney Street,
London SW3 6NP, UK
2Monash Centre of Cardiovascular, Research and Education in Therapeutics,
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reproduction in any medium, provided the orbetter cardiac filling. A series of small mechanistic studies
followed by larger randomized trials have now established
beta-blockers as a key evidence-based treatment to reduce
mortality and morbidity alongside angiotensin converting
enzyme (ACE) inhibitors and aldosterone antagonists.
Current European and American guidelines give a class I
recommendation for the use of beta-blockers in patients
with symptomatic systolic HF [3,4].
However, survey data have confirmed that the uptake
of beta-blockers in HF patients is still sub-optimal. Al-
though the percentage of eligible patients prescribed
beta-blockers increased between the first and second Euro
Heart Failure surveys, a substantial number of patients
remain untreated or receive sub-maximal therapy [5,6].
Paradoxically, those at the greatest risk of death are less
likely to receive evidence-based therapy after a HF
hospitalization [7]. The reasons for this are multi-factoriall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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blockers in HF may make symptoms worse or that beta-
blockers should only be commenced in specialized clinics.
There has also been concern that the evidence-base is not
representative of broader clinical practice and that com-
mon patient groups, including older persons, those with
impaired renal function and diabetes may not benefit.
Although a number of sub-group and meta-analyses
based on published data have been conducted [8,9], these
can only address reported outcomes and are limited statis-
tically. Only an individual patient data (IPD) meta-analysis
is able to explore the effects of treatment on important
secondary outcomes such as sudden death, NYHA class
or ejection fraction and allow reliable pooled sub-group
analyses.
Methods
The Beta-blockers in Heart Failure Collaborative Group
(BB-HF)
The BB-HF group is a collaborative, multinational effort
to combine individual data from the major randomized
controlled trials (RCTs) investigating the use of beta-
blockers in chronic HF. The group consists of the lead-
ing investigators of these trials and international experts,
with the support of the four pharmaceutical companies
that have marketed beta-blockers in HF (AstraZeneca,
GlaxoSmithKline, Merck Serono and Menarini). A full list
of collaborators is presented in Appendix A. Two meet-
ings of the collaborative group in November 2008 and
August 2010 were used to define our objectives, establish
inclusion criteria and develop the primary and secondary
objectives. A standardized data request form was generated
to obtain IPD from each eligible trial (see Additional file 1).
At the time of this publication, individual data on
15,922 participants (representing 10 of the 11 trials) have
been received by the coordinating center, the Clinical
Trials and Evaluation Unit, Royal Brompton & Harefield
NHS Trust/Imperial College London.
Objectives
The aims and objectives of the BB-HF individual patient
data meta-analysis include:
a)Provide a definitive estimate of the overall treatment
effect of beta-blockers in HF on key outcomes
including all-cause mortality and hospitalization.
b)Analyze the influence of important pre-
randomization patient characteristics on the clinical
effects of beta-blockers, including age, diabetes,
gender, ejection fraction, renal function, atrial
fibrillation and the etiology of HF.
c)Pool the adverse event and discontinuation data to
assess the safety of beta-blockers in HF patients,
particularly the rate of bradycardia and hypotension.d)Explore the relationship between the effects of beta
blockers and key baseline measurements including
heart rate, blood pressure and weight.
e)Perform an exploratory analysis to assess important
post-randomization variables, such as change in heart
rate, achieved heart rate, change in blood pressure,
achieved dose and the prescription of other
concomitant therapies, such as ACE inhibitors,
angiotensin receptor blockers (ARB), aldosterone
antagonists, diuretics and digoxin.
f )Describe in detail the effect on hospitalization data
including recurrent hospitalization, total number of
cardiovascular/HF-related hospitalizations and
duration of stay according to treatment allocation.
g)Develop a risk model for patients with HF using key
baseline characteristics to allow clinicians to
accurately assess prognosis in individual patients.
h)Examine the potential economic impact of treatment
under a variety of circumstances and different
subgroups.
i) Improve statistical methodology for IPD meta-
analysis.
Study inclusion criteria
A number of inclusion criteria were adopted to make the
project methodologically sound and technically feasible.
All RCTs of beta-blockers versus placebo explicitly repor-
ting mortality as a primary or combination outcome will
be included but not head-to-head comparisons with an-
other active agent. Trials must include patients with docu-
mented symptomatic HF and only unconfounded trials
will be accepted (in which one treatment group differed
from another only by the beta-blocker therapy of interest).
Finally, RCTs would only be included if they recruited
more than 300 patients in total and planned follow-up of
six months or greater. By concentrating on the larger trials
(which have enrolled 95.7% of all RCT participants), the
project remains practical while the amount of data missed
by not including the smaller trials is minimized.
Search strategy and eligible studies
To ensure a complete assessment of the evidence, pub-
lished or unpublished RCTs were identified through com-
puter aided searches (for example, Medline and Current
Contents), scrutiny of reference lists of trials, trials regis-
tries, meeting abstracts, review articles and discussion
with members of the collaborative group and with the
pharmaceutical manufacturers.
The search identified 11 trials that met all inclusion
criteria (with a predicted total of 18,630 participants);
the Australia/New Zealand Heart Failure Study (ANZ)
[10], the Beta-Blocker Evaluation Survival Trial (BEST)
[11], the Carvedilol Post-Infarct Survival Control in LV
Dysfunction Study (CAPRICORN) [12], the Carvedilol
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cess Study (CHRISTMAS) [13], the Cardiac Insufficiency
Bisoprolol Study (CIBIS I) [14], the Cardiac Insufficiency
Bisoprolol Study II (CIBIS-II) [15], the Carvedilol
Prospective Randomized Cumulative Survival Study
(COPERNICUS) [16], the Metoprolol in Idiopathic
Dilated Cardiomyopathy Study (MDC) [17], the Metoprolol
CR/XL Randomised Intervention Trial in Congestive
Heart Failure (MERIT-HF) [18], the Study of the Effects of
Nebivolol Intervention on Outcomes and Rehospitalisa-
tion in Seniors with Heart Failure Study (SENIORS) [19]
and the U.S. Carvedilol Heart Failure Study (US-HF) [20].
A number of large trials were discussed in detail but were
not included. The Randomized Evaluation of Strategies
for Left Ventricular Dysfunction (RESOLVD) Pilot Study
(n = 426) was excluded as the trial had a multi-factorial
design with two stages of randomization which may have
confounded treatment effect [21]. Further, the beta-
blocker phase of the trial involved a follow-up period of
only 24 weeks. The Carvedilol ACE-Inhibitor Remodelling
Mild CHF Evaluation (CARMEN) trial (n = 572) was
excluded as the study design was a parallel group ran-
domization of carvedilol plus enalapril, carvedilol plus
placebo or enalapril plus placebo and examined effects on
left-ventricular remodeling [22]. Additional discussions
were held regarding the inclusion of CAPRICORN
(the only post-infarct trial) and BEST (utilizing a pharma-
cologically distinct beta-blocker). The Collaborative Group
decided to include these studies, but to perform sensitivity
analyses for the primary outcome, as detailed in the statis-
tical section below. Details of the included trials are pre-
sented in Table 1 and demographic variables in Table 2.
Primary and secondary outcomes
The primary outcome for BB-HF will be all-cause mortality,
including deaths recorded after publication of the trial,
where these data are available. The major secondary out-
come will be the composite of all-cause mortality and car-
diovascular hospitalizations. Secondary mortality outcomes
include death due to acute myocardial infarction (MI),
stroke, sudden cardiac death and HF-related death. Other
secondary outcomes are non-fatal MI, all-cause hos-
pitalization, cardiovascular hospitalization, HF-related
hospitalization and the number and duration of hospital
admissions. Drug safety outcomes will focus on discontinu-
ation due to hypotension, bradycardia, renal impairment
and HF-exacerbation.
Statistical analysis
Due to the complexity of the statistical analyses, the fol-
lowing section represents the planned principal analyses;
some modifications and secondary analyses are likely to
emerge during the project. However, a detailed statistical
analysis plan will be produced prior to the analysis.Careful initial evaluation will be performed to ensure
completeness of data, and to check consistency of the
results of the primary analyses for each trial with pub-
lished reports. Baseline characteristics of patients will be
presented separately for each trial and overall. Continuous
variables will be presented as mean and standard deviation
(or median and range if not normally distributed). Binary
and categorical variables will be presented as frequencies
and percentages. All analyses will follow the principle of
intention to treat as closely as possible. Specifically, we
will include all randomized patients with outcome data.Primary analysis
The primary and major secondary outcome will be ana-
lyzed using a stratified Cox regression model [23], with
studies as strata. Further models will include known prog-
nostic factors for this patient population (for example, age,
gender, baseline ejection fraction, blood pressure, heart
rate, diabetes and renal function). This adjusted analysis
will give estimates that are more relevant to individual
patients. This is a fixed effect approach and assumes that
all trials are estimating a common treatment effect. Stand-
ard tests for heterogeneity will be carried out and as a
sensitivity analysis a random effects approach will be fol-
lowed. Hazard ratios and corresponding 95% confidence
intervals will be presented, along with the corresponding
P-value.Secondary/subgroup analyses
The secondary outcomes will be analyzed in the same
manner as the primary outcome.
Subgroup analyses will be used to assess the effect of
beta-blockers in the following pre-specified subgroups:
age, diabetes, gender, ejection fraction, atrial fibrillation
and etiology of HF. The influence of age and ejection frac-
tion on the effects of beta-blockers will be explored as
continuous variables and as clinically relevant categories
for other variables. A meta-analysis of interaction esti-
mates will be used to assess whether any improvement
depends on baseline LV ejection fraction, blood pressure,
and the presence or absence of other concomitant cardio-
vascular therapies, such as ACE inhibitors, angiotensin re-
ceptor blockers, diuretics and digoxin.
Multiple imputation for missing data will be used where
appropriate as a sensitivity analysis. Dichotomous out-
comes will be combined using an inverse variance meta-
analysis. Odds ratios and corresponding 95% confidence
intervals will be presented, along with the corresponding
P-value. To explore the influence of baseline covariates on
the primary and major secondary outcomes, we will de-
velop multivariable models using the Cox proportional
hazards approach to develop a risk score. In all analyses,
continuous variables will be kept continuous, and the
Table 1 Details of studies proposed for inclusion in meta-analysis
Trial (drug)
by year
n Population Inclusion criteria Exclusion criteria Major endpoints Withdrawal/ Lost
to follow-up
Study period
MDC 383 Symptomatic
IDC
EF <40%; Treatment with BB or CCB; Significant CAD on angiography;
Myocarditis; Life-threatening diseases; COPD requiring beta
agonists; Drug or alcohol abuse; IDDM; Thyroid disease; SBP
<90 mmHg; HR <45
All-cause mortality; Need for
transplantation; exercise capacity;
NYHA, QoL
12% metoprolol,
16% placebo /
18 months (12
after 1990);
additional 3-
year data
(metoprolol) Age 16 to 75
one lost1993
CIBIS 641 Symptomatic
HF
EF <40%; Hypertrophic/restrictive cardiomyopathy; Untreated valve
disease; Awaiting bypass surgery; MI in previous three months;
On heart transplantation list; IDDM; Asthma; Creatinine
>300 μmol/L; Thyroid disease; Life threatening disease; SBP
<100 or >160 mmHg; HR <65
All-cause mortality; Bisoprolol
tolerability (based on NYHA and
adverse events)
23% bisoprolol, 26%
placebo /
Mean 1.9 years
one lostAge 18 to 75; NYHA
III or IV
(bisoprolol)
1994
US-HF 1,094 Symptomatic
HF
EF ≤35%; Major CV event/surgery within three months; Uncorrected
valve disease; Myocarditis; Uncontrolled ventricular
tachycardia/heart block; Clinically important hepatic or renal
disease; Conditions limiting exercise or survival; Treatment with
BB, CCB or class 1C antiarrhythmic agents; SBP <85 or
>160 mmHg; HR <68
All-cause mortality; Hospitalization 5.7% carvedilol,
7.8% placebo /
Median
6.5 months(carvedilol)
zero lost1996
ANZ 415 Symptomatic
HF due to
CAD
EF <45%; Coronary event/procedure within four weeks; Sick sinus, 2nd or
3rd degree heart block; Treadmill exercise duration <2 or
>18 minutes; Myocardial or valvular disease; Treatment with
BB, beta agonist or verapamil; IDDM; COPD; hepatic disease;
Creatinine >250 μmol/L); Life-threatening disease; SBP <90 or
>160 mmHg; HR <50
EF; Exercise duration; NYHA; Death;
Hospitalization
20% carvedilol, 14% Mean
19 monthsplacebo /NYHA II or III
zero lost(carvedilol)
1997
CIBIS II 2,647 Symptomatic
HF
EF <35%; MI/unstable angina within three months; Revascularization
within six months; Prior or scheduled heart transplant;
Uncontrolled 2nd/3rd degree heart block; Creatinine
>300 μmol/L; Reversible COPD; Treatment with BB, CCB or
antiarrhythmic drugs other than amiodarone; SBP <100 mmHg
or uncontrolled hypertension; HR <60
All-cause mortality; All-cause
hospital admissions; CV mortality
15% bisoprolol, 15%
placebo /
Mean 1.3 years
(bisoprolol) NYHA III or IV
six lost1999
MERIT-HF 3,991 Symptomatic
HF
EF ≤40%; MI/unstable angina within 28 days; BB within six weeks, CCB or
amiodarone within six months; Planned or performed
transplantation or implanted defibrillator; Bypass surgery or
percutaneous intervention planned or in last four months;
Uncorrected 2nd/3rd degree heart block; Other serious diseases;
SBP <100 mmHg; HR <68
All-cause mortality; All-cause
mortality plus all-cause
hospitalization
14% metoprolol,
15% placebo /
Mean 1 year
(metoprolol
XL)
Age 40 to 80
zero lost
1999
COPERNICUS 2,289 Severe HF EF <25%; Uncorrected valvular disease or reversible cause; Prior or
planned cardiac transplant; Primary pulmonary or hepatic
disease; Creatinine >247.5 μmol/L; Potassium <3.5 or
>5.2 mmol/L; Coronary revascularization, MI; stroke or
ventricular arrhythmia within two months; Treatment with BB
within two months or alpha-blocker, CCB or class I
antiarrhythmic within four weeks; SBP <85 mmHg; HR <68
All-cause mortality; Hospitalization 15% carvedilol, 19%
placebo /
Mean
10.4 months(carvedilol) NYHA III or IV
zero lost2001
CAPRICORN 1,959 Left
ventricular
dysfunction
post-MI
3 to 21 days post-
MI;
Continued requirement of intravenous diuretics; Unstable
angina; Unstable IDDM; BB indication other than HF; Inhaled
beta agonists or steroids; SBP <90 mmHg or uncontrolled
hypertension; HR <60
All-cause mortality; All-cause
mortality or CV hospitalization;
Sudden death; HF-hospitalization;
Non-fatal events
20% carvedilol, 18%
placebo /
Mean 1.3 years
(carvedilol)
endpoint-drivenEF ≤40%2001
BEST 2,708 Symptomatic
HF
EF <35%; Reversible cause of HF or valvular disease; Untreated thyroid
disease; Obstructive/hypertrophic cardiomyopathy; Pericardial
23% bucindolol,
25% placebo /
Mean 2 years
(bucindolol) NYHA III or IV;
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Table 1 Details of studies proposed for inclusion in meta-analysis (Continued)
disease; Amyloidosis; Myocarditis; MI within six months;
Candidate for heart transplantation; Revascularization within
60 days; Unstable angina; Life expectancy <3 years; Active liver
disease or excess alcohol; Creatinine >265 μmol/L; Other
serious diseases; Treatment with BB within 30 days, CCB or
beta-agonists within one week, class 1 antiarrhythmic within
two weeks or amiodarone within eight weeks; SBP
<80 mmHg; HR <50
All-cause mortality; Death from CV
causes; Hospitalization; EF; Non-
fatal MI; QoL
eight lost2001 Digoxin in all
patients pre-1997
CHRISTMAS 375 Stable HF
due to CAD
EF <40%; Women of child-bearing age; Acute CV event within three
months; Hospital admission within one month; Unstable
angina; Arrhythmias (for example, atrial fibrillation);
Uncontrolled hypertension; COPD; Poorly controlled diabetes;
Clinically relevant renal or hepatic disease; Treatment with
non-dihydropiridine CCB, BB or antiarrhythmic other than
amiodarone; SBP <85 mmHg; HR <60
Change in EF (hibernators vs. non-
hibernators);
15% carvedilol, 7%
placebo /
Mean
6.3 months(carvedilol) Age ≥40 years;
one lostRegional echocardiographic
contractile dysfunction;
2003 NYHA I to III
Death or worsening HF.
SENIORS 2,128 Elderly HF Age ≥70; Uncorrected valvular disease; Current use of BB; Significant
hepatic or renal dysfunction; Stroke within three months;
Pending coronary revascularization; Other serious medical
conditions reducing survival; SBP <90 mmHg; HR <60
All-cause mortality or CV
hospitalization; All-cause mortality;
All-cause hospitalization; NYHA
27% nebivolol, 25%
placebo /
Mean
21 months(nebivolol) HF-hospitalization
within 12 months or
EF ≤35% within
6 months
37 lost2005
BB, beta-blocker; CAD, coronary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; EF, ejection fraction; HF, heart failure; HR, heart rate; IDC, idiopathic
dilated cardiomyopathy; IDDM, insulin-dependent diabetes mellitus; MI, myocardial infarction; NYHA, New York Health Association; QoL, quality of life; SBP, systolic blood pressure.
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tional polynomials.
As noted above, we also plan to perform sensitivity
analyses for the exclusion (separately) of the BEST and
CAPRICORN trials. If data from the eligible trials are
unobtainable, then analysis using a combination of IPD
and aggregate data will be considered [24].
For the economic analysis, we propose to perform a cost
analysis using standard published information to provide a
representative spread of health economic scenarios. Costs
of care will be derived from simple drivers like hospital
length of stay, medications and other treatments and a
cost effectiveness analysis will be carried out based on cost
per event avoided (for example, death or hospital admis-
sion). Modeling of cost effectiveness will be carried out
based on specific subgroups, such as age, gender and
diabetes, in a number of different healthcare models (for
example, socialized care, private care and a mixed health
care model), taking account of the different costs of beta-
blockers. An overall population-based cost impact analysis
will be derived assessing different levels of uptake of beta-
blockers in heart failure with a view to estimating the cost
savings of improving beta-blocker utilization.Discussion
Despite a wealth of information identifying the overall
benefits of beta-blockers in HF for morbidity and mor-
tality, prescription rates remain sub-optimal with conse-
quence for both patients and healthcare providers.
Current data are limited to those enrolled in the RCTs
and lack sufficient statistical power to examine the harm
and benefits of treatment in important patient sub-
groups. For example, diabetes is present in about 25% of
patients enrolled in the larger trials of beta-blockers inTable 2 Patient characteristics of studies proposed for inclusi
Trial (drug) by Year n Mean age Male Mean EF
MDC (metoprolol) 1993 383 49 72% 22%
CIBIS (bisoprolol) 1994 641 60 83% 25%
US-HF (carvedilol) 1996 1,094 58 77% 23%
ANZ (carvedilol) 1997 415 67 80% 29%
CIBIS II (bisoprolol) 1999 2,647 61 80% 28%
MERIT-HF (metoprolol XL) 1999 3,991 64 78% 28%
COPERNICUS (carvedilol) 2001 2,289 63 80% 20%
CAPRICORN (carvedilol) 2001 1,959 63 74% 33%
BEST (bucindolol) 2001 2,708 60 78% 23%
CHRISTMAS (carvedilol) 2003 (375)* 63 90% 29%
SENIORS (nebivolol) 2005 2,128 76 63% 36%
TOTAL / WEIGHTED MEAN 18,630 63 77% 27%
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; E
pressure.
* Characteristics reported are for the 305 participants with available radionuclide veHF. The risk of mortality and other complications is
higher in diabetics but meta-analysis of published tabu-
lar data has suggested that the absolute mortality reduc-
tion using beta-blockers may be less in patients with
diabetes [25]. We will update this analysis by including
data from four additional studies and uniquely, will be
able to adjust for baseline covariates which may account
for much of the apparent difference in effect.
Perhaps the most important patient factor that affects
prescription of evidence-based therapy is age. In most
population-based studies the incidence and prevalence of
HF increases with age and the average age of prevalent HF
is about 75 years. Most of the trials enrolled patients with
a mean age of 60 to 65 years; only SENIORS recruited a
population of 70 years or older. The proposed meta-
analysis will allow a reliable exploration of any interaction
on the effect of beta-blockers with age, albeit limited to
the populations recruited in the individual studies. Simi-
larly, most of the trials have enrolled patients with systolic
dysfunction (entry ejection fraction <40%; see Table 1) and
an interaction between baseline ejection fraction and the
benefit of beta-blockers may exist [26].
Women with HF are under-represented in the literature
and account for less than a quarter of patients in the trials
listed in Table 1. Further, the benefits of beta-blockade in
women are inconsistent. In the pooled CIBIS trials, all-
cause mortality was similarly reduced in men and women
[27] and in the US-HF study women apparently benefited
more from beta-blockade (hazard ratio 0.23, 0.07 to 0.69)
than men (0.41, 0.22 to 0.80) [20]. In comparison, the
results from BEST, MERIT-HF and COPERNICUS found
no significant benefit in women [16,28,29]. Gender also
has important consequences on evaluation, treatment and
prognosis in HF. We know that women with HF have dif-
ferent prognostic indicators than men, such as older age,on in meta-analysis
Diabetes On ACEi/ARB Mean SBP (mmHg) Mean HR (bpm)
n/s 79% 118 91
n/s 90% 126 83
29% 95% 116 84
19% 85% n/s n/s
12% 96% 130 80
25% 96% 130 83
26% 97% 123 83
22% 98% 121 77
36% 98% 117 82
22% 87% 126 78
26% 89% 139 79
23% 95% 126 81
F, ejection fraction; HR, heart rate; n/s, not specified; SBP, systolic blood
ntriculograms, as per the original publication.
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likely to receive guideline therapies, and have longer hos-
pital stays [28,30,31].
There are also concerns that beta-blockers may worsen
renal function in HF by reducing renal blood flow and
glomerular filtration rate. Renal impairment is a common
co-morbidity in HF that limits therapy. However, existing
(under-powered) data suggest that beta-blockers are
effective regardless of baseline renal function [32,33]. We
aim to model the effects of beta-blockers stratified by
renal function as a continuous variable, adjusting these
effects for other covariates which is impossible in a simple
tabular analysis. Other important controversies that can
be addressed by this IPD analysis include the effects of
beta-blockers in patients with HF and atrial fibrillation
[34-36], and the interaction of benefit with heart rate,
blood pressure changes and achieved dose [37,38]. We will
also use the data to develop new insights into risk factors
for death and hospitalization in HF patients. There are
also important safety issues to explore, including the risk
of adverse events, such as hypotension and bradycardia.
Finally, although IPD meta-analyses are considerably
more resource-intensive and time-consuming than stand-
ard tabular approaches, we believe that only IPD can
address the unanswered questions about the use of beta-
blockers in HF. Extraction of data from published reports
has significant limitations; typically outcomes are des-
cribed as the number of participants that have died on
each intervention over a fixed period, yielding an odds
ratio. In comparison, IPD allows a full time-to-event ana-
lysis addressing each event from the time of randomization.
The hazard ratio obtained provides a more appropriate
view of survival and accounts for censored patients. As
previously described, IPD also permits robust analyses of
subgroups and the ability to estimate the interaction be-
tween covariates and treatment effect [39]. The combined
sample sizes for the major variables of interest are sufficient
to provide statistical power and conclusive data on the
safety and efficacy of beta-blockers in HF patients.
In summary, this individual patient-data systematic
review and meta-analysis will provide a definitive assess-
ment of the role of beta-blockers in heart failure. The aims
of the Collaborative Group are to reduce the burden of
morbidity and mortality in heart failure patients and pro-
vide clinicians and healthcare agencies with clear guidance
on which patients will benefit from beta-blocker therapy.
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